CGTLive®’s Weekly Rewind – May 24, 2024

News
Article

Review top news and interview highlights from the week ending May 24, 2024.

CGTLive®’s Weekly Rewind

CGTLive®’s Weekly Rewind

Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Atara Submits BLA for Tab-Cel EBV+ PTLD T-Cell Therapy

Tab-Cel is approved under the name Ebvallo in Europe, Switzerland, and United Kingdom.

2. Leigh Ramos-Platt, MD, on Allowing Access and Ensuring Preparation for Gene Therapies

The Associate Professor of Neurology at Keck School of Medicine of USC discussed her talk on preparing for gene therapy administration.

3. CRISPR-Editing EBT-101 Therapy Safe, Temporarily Suppresses HIV Infection

Excision is evaluating a higher dose in a second cohort as well as exploring alternative, potentially redosable, delivery methods.

4. Erika Fullwood Augustine, MD, MS, on Optimizing End Points for Rare Disease Clinical Trials

The associate chief science officer of the Kennedy Krieger Institute discussed an aspect of clinical trial design highly relevant to gene therapy development for rare diseases.

5. NKGen’s Autologous NK Therapy Proceeds to Phase 2 Trial for Alzheimer Disease

Most participants had improved or stable cognitive function in a proof-of-concept study.

Recent Videos
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Sarah Hein, PhD, the chief executive officer and cofounder of March Biosciences
Kiran Musunuru, MD, PhD, a physician-scientist and Barry J. Gertz Professor for translational research in the Perelman School of Medicine at the University of Pennsylvania and CHOP and Rebecca Ahrens-Nicklas, MD, PhD, a physician-scientist and director of the Gene Therapy for Inherited Metabolic Disorders Frontier Program at CHOP
Kiran Musunuru, MD, PhD, a physician-scientist and Barry J. Gertz Professor for translational research in the Perelman School of Medicine at the University of Pennsylvania and CHOP and Rebecca Ahrens-Nicklas, MD, PhD, a physician-scientist and director of the Gene Therapy for Inherited Metabolic Disorders Frontier Program at CHOP
Kiran Musunuru, MD, PhD, a physician-scientist and Barry J. Gertz Professor for translational research in the Perelman School of Medicine at the University of Pennsylvania and CHOP and Rebecca Ahrens-Nicklas, MD, PhD, a physician-scientist and director of the Gene Therapy for Inherited Metabolic Disorders Frontier Program at CHOP
Related Content
© 2025 MJH Life Sciences

All rights reserved.